INPROSUB SOLUTION

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

PROGESTERONE

থেকে পাওয়া:

IBSA INSTITUT BIOCHIMIQUE SA

এটিসি কোড:

G03DA04

INN (আন্তর্জাতিক নাম):

PROGESTERONE

ডোজ:

25MG

ফার্মাসিউটিকাল ফর্ম:

SOLUTION

রচনা:

PROGESTERONE 25MG

প্রশাসন রুট:

SUBCUTANEOUS

প্যাকেজ ইউনিট:

100

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

PROGESTINS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0106327010; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2021-04-30

পণ্য বৈশিষ্ট্য

_INPROSUB™ (progesterone injection) _
_ _
_Page 1 of 33_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
INPROSUB™
Progesterone Injection
Solution, 25 mg / 1.112 mL (22.5 mg / mL) progesterone, subcutaneous
injection
House Standard
Progestin
Institut Biochimique SA (IBSA)
Via del Piano 266
CH-6915 Pambio-Noranco,
Switzerland
Imported by:
Progress Therapeutics Inc.
14-320 Harry Walker Parkway North
Newmarket ON
Canada, L3Y 7B4
Date of Initial Authorization:
June 21, 2021
Submission Control No: 239820
_ _
_INPROSUB™ (progesterone injection) _
_Page 2 of 33_
TABLE OF CONTENTS
TABLE OF CONTENTS
.......................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION ....................................................... 4
1
INDICATIONS ...........................................................................................................
4
1.1
Pediatr
ics.............................................................................................................4
1.2
Ger iatr
ics.............................................................................................................4
2
CONTRAINDICATIONS ...........................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
.............................................................. 5
4
DOSAGE AND ADMINISTRATION .........................................................................
5
4.1
Dosing Considerations
.........................................................................................5
4.2
Recommended Dose and Dosage Adjustment
.......................................................5
4.3
Administration.....................................................................................................5
4.4
Missed Dose
........................................................................................................6
5
OVERDOSAGE ......................................................